Abdelhaleem Marwa, Saleh Wafaa, Elmeadawy Samah
Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Horus University, New Damietta, Egypt.
Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Mansoura University, Mansoura, 33516, Egypt.
BMC Oral Health. 2025 Jan 14;25(1):63. doi: 10.1186/s12903-024-05398-w.
The current literature about the effect of advanced platelet rich fibrin(A-PRF) with vestibular incision subperiosteal tunnel access (VISTA) technique in treating gingival recession is scarce. Therefore, the aim of the current randomized clinical trial is to evaluate the effect of A-PRF with VISTA technique in the treatment of Cairo class 1 gingival recession (RT1).
Twenty-four patients who met the eligibility criteria were randomly allocated into two groups. VISTA + A-PRF was the treatment of the study group, while VISTA + collagen matrix was performed for the control group. The clinical outcomes were assessed by a single-blind assessor at baseline, three months, and six months. They were divided into primary and secondary outcomes. The primary outcomes included recession depth (RD), recession width (RW), gingival thickness (GT), mean of root coverage % (MRC%), and width of attached gingiva (WAG) while the secondary outcome included clinical attachment level (CAL).
The primary outcomes analysis demonstrated statistically significant improvements in RD, RW, MRC%, GT, and WAG after 3 and 6 months in both groups (p < 0.001). However, the study group demonstrated a significantly greater improvement than the control group in RD, RW, and MRC%. No significant differences were observed between the two groups regarding GT and WAG.
Both treatment approaches were effective in the treating of RT1 adjacent gingival recessions. A-PRF showed promising results compared to collagen matrix.
The current randomized clinical trial was registered at ClinicalTrials.gov (Registration number: NCT06357351) and it was released on 10/04/2024.
目前关于采用前庭切口骨膜下隧道入路（VISTA）技术联合高级富血小板纤维蛋白（A-PRF）治疗牙龈退缩效果的文献较少。因此，本随机临床试验的目的是评估VISTA技术联合A-PRF治疗开罗1类牙龈退缩（RT1）的效果。
将24例符合纳入标准的患者随机分为两组。研究组采用VISTA联合A-PRF治疗，而对照组采用VISTA联合胶原基质治疗。由单盲评估者在基线、3个月和6个月时评估临床结果。这些结果分为主要结果和次要结果。主要结果包括退缩深度（RD）、退缩宽度（RW）、牙龈厚度（GT）、平均牙根覆盖百分比（MRC%）和附着龈宽度（WAG），次要结果包括临床附着水平（CAL）。
主要结果分析表明，两组在3个月和6个月时RD、RW、MRC%、GT和WAG均有统计学意义的显著改善（p<0.001）。然而，研究组在RD、RW和MRC%方面的改善明显大于对照组。两组在GT和WAG方面未观察到显著差异。
两种治疗方法对治疗相邻的RT1牙龈退缩均有效。与胶原基质相比，A-PRF显示出有前景的结果。
本随机临床试验已在ClinicalTrials.gov注册（注册号：NCT06357351），于2024年4月10日发布。
Zotero 插件
